Shots:
- The US FDA has approved Aptar’s Cardamyst (Etripamil), developed by Milestone Pharmaceuticals, for the conversion of acute symptomatic episodes of paroxysmal supraventricular tachycardia (PSVT) to sinus rhythm in adults
- Cardamyst (Intranasal) is a Bidose (BDS) Liquid Nasal Spray System
- Aptar collaborated with Milestone Pharmaceuticals to design a custom polypropylene container closure system with an integrated cap for Cardamyst
Ref: Milestone Pharma| Image: Milestone Pharma| Press Release
Related News: HUTCHMED Reports NMPA’s NDA Acceptance with Priority Review of Savolitinib for Gastric Cancer Patients with MET Amplification
PharmaShots, your go-to media platform for customized news ranging across multiple indications. For more information, connect with us at connect@pharmashots.com
